Ultragenyx Pharmaceutical Inc. (RARE) Profit Margins
Over the twelve months to 2026-06-30, Ultragenyx Pharmaceutical Inc. (RARE) had gross margin 83.1%, operating margin -73.6%, net margin -81.7%, free cash flow margin -68.2%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RAREUltragenyx Pharmaceutical Inc.Follow RARE — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 100.0% | 97.8% | — | — | — | — | 89.6% | 86.3% | 83.8% | 83.1% | |
| Operating margin | -12593.5% | -721.2% | -409.0% | -121.8% | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% | -73.6% | |
| Net margin | -11567.3% | -383.7% | -388.3% | -68.8% | -129.2% | -194.7% | -139.9% | -101.6% | -85.4% | -81.7% | |
| FCF margin | -9825.3% | -572.2% | -357.0% | -65.0% | -117.2% | -136.7% | -119.6% | -75.2% | -70.1% | -68.2% |
USD billions · SEC XBRL
Ultragenyx Pharmaceutical Inc. — questions
- What is Ultragenyx Pharmaceutical Inc.'s gross margin?
- 83.1% over the twelve months to 2026-06-30.
- What is Ultragenyx Pharmaceutical Inc.'s operating margin?
- -73.6% over the twelve months to 2026-06-30.
- What is Ultragenyx Pharmaceutical Inc.'s net profit margin?
- -81.7% over the twelve months to 2026-06-30.
Every figure on this page comes from Ultragenyx Pharmaceutical Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.